EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Safety and tolerability of Empagliflozin use during the holy month of Ramadan by fasting patients with type 2 diabetes: A prospective cohort study

Mayada M Samkari, Neda'a S Bokhari, Raghad Alhajaji, Malaz E Ahmed, Ahmad Al Raddadi, Alaa K Bahget, Sarah F Saleh, Faisal Aljehani, Saud H Alzahrani, Sarah S Alsifyani, May M Samkari, Aisha F Badr und 2 weitere

Saudi Pharmaceutical Journal · 2023-06 · 31 (6) · 972-978

DOI: 10.1016/j.jsps.2023.04.022 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Saudi Pharmaceutical Journal, 2023-06. Verfasst von Mayada M Samkari und 13 weiteren Autor:innen. Beteiligte Einrichtung: Diabetic and Endocrine Center, Al-Noor Specialist Hospital, Makkah Healthcare Cluster, Makkah, Saudi Arabia. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Type 2 Diabetes Mellitus (T2DM) patients are exposed to a 7.5 times higher risk of hypoglycemia while fasting during Ramadan. Relevant diabetes guidelines prioritize the use of SGLT2 inhibitors over other classes. There is a great need to enrich data on their safe and effective use by fasting patients at greater risk of hypoglycemia. Therefore, this study aims to assess the safety and tolerability of Empagliflozin in T2DM Muslim patients during Ramadan. Methodology: A prospective cohort study was conducted for adult Muslim T2DM patients. Patients who met the inclusion criteria were categorized into two sub-cohorts based on Empagliflozin use during Ramadan (Control versus Empagliflozin). The primary outcomes were the incidence of hypoglycemia symptoms and confirmed hypoglycemia. Other outcomes were secondary. All patients were followed up to eight weeks post-Ramadan. A propensity score (PS) matching and Risk Ratio (RR) were used to report the outcomes.

Results

Among 1104 patients with T2DM who were screened, 220 patients were included, and Empagliflozin was given to 89 patients as an add-on to OHDs. After matching with PS (1:1 ratio), the two groups were comparable. The use of other OHDs, such as sulfonylurea, DPP4 inhibitors, and Biguanides, was not statistically different between the two groups. The risk of hypoglycemia symptoms during Ramadan was lower in patients who received Empagliflozin than in the control group (RR 0.48 CI 0.26, 0.89; p-value = 0.02). Additionally, the risk of confirmed hypoglycemia was not statistically significant between the two groups (RR 1.09 CI 0.37, 3.22; p-value = 0.89).

Conclusion

Empagliflozin use during Ramadan fasting was associated with a lower risk of hypoglycemia symptoms and higher tolerability. Further randomized control trials are required to confirm these findings.

Schlagwörter

Stichwörter der Autor:innen

EmpagliflozinFastingHyperglycemiaHypoglycemiaMuslimsRamadanSGLT2 inhibitorsSodium-glucose co-transporter 2 inhibitorsT2DM

Autor:innen und Institutionen

  • Diabetic and Endocrine Center, Al-Noor Specialist Hospital, Makkah Healthcare Cluster, Makkah, Saudi Arabia.
  • Health Programs Administration, Makkah Health Affairs, Ministry of Health, Makkah, Saudi Arabia.
  • Al-Magrah Primary Health Care, Primary Care Administration, Makkah Healthcare Cluster, Makkah, Saudi Arabia.
  • College of Medicine, Department of Internal Medicine, University of Jeddah, Jeddah, Saudi Arabia.
  • Public Health Administration, Makkah Health Affairs, Ministry of Health, Makkah, Saudi Arabia.
  • North Obhor PHC-Ministry of Health, Jeddah, Saudi Arabia.

Zitieren

APA

Samkari, M. M., Bokhari, N. S., Alhajaji, R., Ahmed, M. E., Al Raddadi, A., Bahget, A. K., Saleh, S. F., Aljehani, F., Alzahrani, S. H., Alsifyani, S. S., Samkari, M. M., Badr, A. F., Alalawi, M., & Al Sulaiman, K. (2023). Safety and tolerability of Empagliflozin use during the holy month of Ramadan by fasting patients with type 2 diabetes: A prospective cohort study. Saudi Pharmaceutical Journal, 31(6), 972-978. https://doi.org/10.1016/j.jsps.2023.04.022

Vancouver

Samkari MM, Bokhari NS, Alhajaji R, Ahmed ME, Al Raddadi A, Bahget AK, et al. Safety and tolerability of Empagliflozin use during the holy month of Ramadan by fasting patients with type 2 diabetes: A prospective cohort study. Saudi Pharmaceutical Journal. 2023;31(6):972-978. doi:10.1016/j.jsps.2023.04.022

BibTeX
@article{Samkari2023,
  author = {Samkari, Mayada M and Bokhari, Neda'a S and Alhajaji, Raghad and Ahmed, Malaz E and Al Raddadi, Ahmad and Bahget, Alaa K and Saleh, Sarah F and Aljehani, Faisal and Alzahrani, Saud H and Alsifyani, Sarah S and Samkari, May M and Badr, Aisha F and Alalawi, Mai and Al Sulaiman, Khalid},
  title = {Safety and tolerability of Empagliflozin use during the holy month of Ramadan by fasting patients with type 2 diabetes: A prospective cohort study},
  journal = {Saudi Pharmaceutical Journal},
  year = {2023},
  volume = {31},
  number = {6},
  pages = {972--978},
  doi = {10.1016/j.jsps.2023.04.022}
}
Kostenlos starten →